Search clinical trials for: Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)

Total 103 results

Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Active, not recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Botswana, Uganda, South Africa
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
Janssen Sciences Ireland UC
ViiV Healthcare

Approved for marketing

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

HIV
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

Healthy

United States
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
ViiV Healthcare
GlaxoSmithKline; PPD

Recruiting

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOLITION)

HIV Infections

United States, Italy, Spain, Argentina, Germany, France, Canada, Chile, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

HIV-1-infection

United States, Brazil, South Africa, Uganda, Botswana, Thailand
Janssen Sciences Ireland UC

Completed

Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet

Healthy

Belgium
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Healthy

United States
Yale University
ViiV Healthcare

Not yet recruiting

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Hiv

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

HIV Infections
Chiang Mai University

Unknown

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

HIV-1-infection | Neurocognitive Dysfunction

Thailand
St Stephens Aids Trust

Completed

Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.

HIV Infection

United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Healthy

United States, Netherlands
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
University College, London
London School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaborators

Active, not recruiting

Long-Acting Treatment in Adolescents (LATA) (LATA)

HIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus Infection

Uganda, Zimbabwe, Kenya, South Africa
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
ASST Fatebenefratelli Sacco
Elisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.

Completed

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Human Immunodeficiency Virus

Italy
ViiV Healthcare

Completed

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

HIV Infections

Spain
Novartis Pharmaceuticals

Approved for marketing

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (ACCESS)

Acromegaly

United States
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
Fundacion SEIMC-GESIDA

Active, not recruiting

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (MAFALDA-R)

HIV Infections | Fatty Liver Disease

Spain
Novartis Pharmaceuticals

Completed

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Metastatic Melanoma and Merkel Cell Carcinoma

Germany, Switzerland
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Terminated

Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

Hepatitis C

Taiwan
National Institute of Allergy and Infectious Diseases...
National Institute of Mental Health (NIMH)

Withdrawn

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

HIV Infections
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

HIV Infections

Brazil, United States, South Africa, Peru, Thailand, Argentina, Vietnam
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

HIV-1 Infection

United States
Novartis

Completed

Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Germany
Modra Pharmaceuticals

Completed

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States, Germany, Hungary, Poland, Russian Federation, Czechia
Anu Sharma

Terminated

Propranolol in Treating Hypoglycemia Unawareness

Type 1 Diabetes Mellitus

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HIV Infections

Zimbabwe, South Africa, Botswana, Kenya, Malawi, Uganda, Swaziland
Mela, Mansfield, M.D.

Unknown

Propranolol Treatment of Traumatic Memories (PTTM) (PTTM)

Posttraumatic Stress Disorder | Traumatic Memory

Canada
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
Mahidol University

Completed

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (STEREOS)

Dyslipidemias | HIV-1-infection | Sustained Virologic Response | Anti-Retroviral Agents | Efavirenz | Rilpivirine
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
BRC Operations Pty. Ltd.

Unknown

International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder

United States, Australia, Netherlands
University of Alabama at Birmingham

Completed

Combined Behavioral and Drug Treatment of Overactive Bladder in Men (COBALT)

Overactive Bladder | Lower Urinary Tract Symptoms

United States
Tocagen Inc.

Withdrawn

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Bladder Cancer

3

Subscribe